Funding
Funding not disclosed
Founders
Product
Problem
Patients seeking pain management often face challenges with traditional medication, including slow onset, inconsistent dosage, and potential for adverse effects. Existing medicinal cannabis products, particularly oil-based formulations, can exhibit variable absorption rates and delayed therapeutic effects.
Solution
Promethean BioPharma develops advanced medicinal cannabis formulations designed for improved patient outcomes. Their proprietary water-based dissolvable tablets offer a rapid onset of action, significantly faster than conventional oil-based products. This delivery system ensures precise dosage regulation and enhanced bioavailability, leading to up to 60% absorption. The company is actively pursuing clinical trials to establish these products as accessible over-the-counter treatments, aiming to provide an effective alternative for pain management and potentially reduce reliance on other medications.
Target Audience
The primary target audience includes healthcare professionals seeking effective pain management solutions for their patients, as well as patients looking for advanced, reliable, and rapidly acting therapeutic options.
Features
- Water-based dissolvable tablet formulation for rapid sublingual absorption.
- Proprietary technology enabling precise dosage control and consistent delivery.
- Demonstrated onset of action 4-10 times faster than oil-based medicinal cannabis.
- Achieves up to 60% absorption rate, maximizing therapeutic efficacy.
- Focus on THC-free formulations for broad patient applicability.
- Undergoing clinical trials for over-the-counter (OTC) medication status.
- GMP-accredited manufacturing facilities ensuring quality and compliance.
- Integrated supply chain and distribution network for global market access.